Novo Nordisk As operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novo Nordisk As with three other
pharmaceutical manufacturers in Europe:
of UNITED KINGDOM
sales of £20.59 billion [US$28.33 billion]
of which 41%
Lonza Group AG
(4.51 billion Swiss Francs [US$4.88 billion]
of which 99%
was Pharma&Biotech), and
based in GERMANY
(17.53 billion Euros [US$20.34 billion]
of which 43%
was Life Science).
During the second
quarter of 2021, sales at Novo Nordisk As totalled
33.04 billion Danish Kroner.
an increase of 10.1%
from the 30.01 billion Danish Kroner in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled 66.85 billion Danish Kroner, which is
than through the first two quarters of 2020.
During the year ended December of 2020, sales at
Novo Nordisk As were 126.95 billion Danish Kroner (US$19.79 billion).
increase of 4.0%
versus 2019, when the company's sales were 122.02 billion Danish Kroner.
This was the third consecutive year of growth at Novo Nordisk As.
Sales of Diabetes and Obesity saw an increase
5.0% in 2020, from
102.84 billion Danish Kroner to 108.02 billion Danish Kroner.
Not all segments of Novo Nordisk As experienced an increase in sales in 2020:
sales of Biopharmaceuticals fell 1.3% to 18.93 billion Danish Kroner.